GenScript Biotech Corporation has announced the expansion of its Singapore facility to provide a premium gene synthesis service. The move adds an additional 976 square meters to the facility, bringing the total production footprint in Singapore to 3,500 square meters, and making it the third-largest GenScript facility worldwide. The expansion will also increase the total headcount at the Singapore facility to 150.

In February 2022, GenScript Asia-Pacific announced the opening of new recombinant protein production facility; now, that same facility will offer an advanced gene-synthesis service. This marks a significant expansion of the company's advanced gene-synthesis capability and enables GenScript to provide the premium service levels required for novel vaccine and therapeutics development in life sciences.

The Singapore facility houses state-of-the art automated workstations capable of synthesising more than 400 genes per day. It combines advanced, fast-turnaround technology, 70+ PhD-level professionals, and 24-hour technical support to enable biotechs and research facilities to achieve their most ambitious goals.

The new facility aims to reduce project turnaround time for an increasingly global mix of customers while ensuring customer data are secured in Singapore. The capacity of the new facility is committed to support cell and gene therapy research and vaccine development programmes.